Trametinib offers new treatment option for rare form of ovarian cancer | Treatment for Oropharyngeal Cancer: Investigating Ways to Do Less Harm - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.     Trametinib Is a New Treatment Option for Rare Form of Ovarian Cancer 03/10/2022 New results from a large study show that trametinib (Mekinist) is an effective treatment for a rare type of ovarian cancer called low-grade serous ovarian cancer treated with trametinib (Mekinist). Treatment for Oropharyngeal Cancer: Investigating Ways to Do Less Harm This May 2021 Cancer Currents story has been updated to reflect recently presented data from two clinical trials of treatment de-escalation for HPV-positive oropharyngeal cancers.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892